Healthcare

Results offers the skills of an experienced and entrepreneurial healthcare team dedicated to the life sciences sector having closed more than 75 successful transactions to date. Our clients trust us because of our strong international relationships with shareholders and management teams across the healthcare lifecycle. We combine expert financial capabilities with backgrounds in science, healthcare and IT that will bring value to your business.

We work with businesses and entrepreneurs to help articulate the ideal equity story, target the right investors and negotiate the best deal.

• Full service offering for Healthcare M&A transactions, for both buyers and sellers
• Advice on strategic options for healthcare businesses and assets
• Expert guidance on development capital, utilisation of investments or finance for MBO/MBI
• Support for licensing transactions for research assets and marketed products

Healthcare Sub-Sectors

Our highly specialised, global team works together seamlessly across six focus areas in the healthcare sector.

Healthcare Deals

Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has received a significant investment from
Nov 2021
has made an investment in
company name confidential
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Jun 2021
has acquired a drug product manufacturing facility from
Jun 2021
has been acquired by
May 2021
has been acquired by
a Behrman Capital-backed company
May 2021
has formed a strategic alliance with

Latest Insights

Insights
19th January 2022

Predictions for Life Sciences Industries for 2022, and no ‘San Francisco’ This Year!

The Covid 19 pandemic continues to have a major impact on the healthcare industry, both positive if you are close to the discovery and provision of treatments for this infection and negative if you are selling certain other drugs, such as antibiotics or providing care services, which have been negatively impacted by this pandemic. However, […]

Reports
10th November 2021

CDMO Market Update

We are pleased to share with you the CDMO Market Update – November 2021, where we analyse global M&A activity and public market valuations in the CDMO sector. H1 2021 was an exceptional start to the year with 48 deals in total in the CDMO sector, almost reaching the total annual transactions in the previous four […]

Insights
17th May 2021

The next chapter: Changing market dynamics in commercialisation and medical communications

The last twelve months have been a time of extraordinary activity in the commercialisation sector – the COVID-19 pandemic saw medcomms groups play a crucial part in keeping pharma companies connected with patients and healthcare professionals, and dealmaking was frenetic on both sides of the Atlantic, for smaller agencies as well as for emerging ‘CCOs’. […]